GAMMA Investing’s Corvus Pharmaceuticals CRVS Stock Holding History

GAMMA Investing’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.1K	Buy	679 +79	+13%	+$1.1K	﹤0.01%	3197
2026 Q1	$8.78K	Buy	600 +457	+320%	+$7.29K	﹤0.01%	3135
2025 Q4	$1.1K	Buy	143 +49	+52%	+$386	﹤0.01%	3763
2025 Q3	$693	Buy	+94	New	+$481	﹤0.01%	3671

Other funds holding CRVS

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

AIM

Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing's CRVS Position: Q2 2026 in Review

GAMMA Investing increased its Corvus Pharmaceuticals (CRVS) stake by 13% in Q2 2026, buying an estimated $1.1K and bringing the position to 679 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3197.

GAMMA Investing first reported a position in CRVS in Q3 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

GAMMA Investing held 679 shares of Corvus Pharmaceuticals worth $10.1K as of Q2 2026.
GAMMA Investing bought 79 Corvus Pharmaceuticals shares in Q2 2026, an estimated $1.1K.
Corvus Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3197 holding.
GAMMA Investing first reported a position in Corvus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
8 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.